June 02, 2025 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma. These five-year follow-up resul

- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 May 29, 2025 -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A financing led by Atlas Venture, with participation from Acce

May 27, 2025 -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship journal of the American Society of Gene & Cell Therapy. These data supported the advancement of FLT201 into clinical development and highlight its potential to improve upon the current standard of care. “FLT201 was designed to address the shortcomings of existing therapie

May 29, 2025 -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been dosed with AUTX-703 in a first-in-human, Phase 1 clinical trial for patients with advanced hematologic malignancies (NCT06846606). AUTX-703 is a novel, first-in-class, orally available KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ May 29, 2025 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the first participant dosed in the first c

AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or moderate Parkinson’s disease (PD) through 18 months post-gene transfer Non-motor assessments remained numerically stable throughout 18-month follow-up in mild and moderate cohorts Recruitment is ongoing in Europe and the United States for Phase 2 REGENERATE-PD trial to further explore the potential of AB-1005 in participants with moderate PD AskBio Inc. (AskBio), a gene therapy company wholly owned

– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – May 27, 2025 -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC)

May 27, 2025 -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $

May 27, 2025 -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain. Avalyn’s poster presentation at EULAR 2025 will include the Phase 2b study design of AP01 (inhaled pirfenidone) in various forms of progressive pulmonary fibrosis (PPF), including autoim

Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting May 27, 2025 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti